Resverlogix Corp. Total Assets
Resverlogix Corp. total assets. Based on the latest financial reports, Resverlogix Corp. (RVX) holds total assets worth CA$8.24 Million CAD (≈ $5.96 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Resverlogix Corp. for the company's overall valuation and market capitalisation.
Total Assets of Resverlogix Corp. (2001–2025)
Total assets of Resverlogix Corp. from 2001 to 2025. This chart illustrates how Resverlogix Corp.'s total assets have evolved over time, based on quarterly financial data. See latest Resverlogix Corp. stock price today for real-time trading data and today's change.
Resverlogix Corp. - Asset Composition Analysis
Resverlogix Corp. Total Assets Breakdown (December 2025)
Resverlogix Corp. total assets breakdown as of December 2025. Resverlogix Corp.'s total assets of CA$8.24 Million consist of 20.2% current assets and 79.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 1.4% |
| Accounts Receivable | CA$910.34K | 11.5% |
| Inventory | CA$434.21K | 5.5% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$2.58 Million | 32.6% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Resverlogix Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Resverlogix Corp. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Resverlogix Corp.'s current assets represent 20.2% of total assets in 2025, a decrease from 100.0% in 2001.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 99.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 32.6% of total assets.
Resverlogix Corp. Competitors by Total Assets
Key competitors of Resverlogix Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Resverlogix Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.04 | 0.28 |
| Quick Ratio | 0.03 | 0.02 | 0.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-43.28 Million | CA$-37.47 Million | CA$-10.59 Million |
Resverlogix Corp. - Advanced Valuation Insights
This section examines the relationship between Resverlogix Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 47.93 |
| Latest Market Cap to Assets Ratio | 2.35 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | CA$7.93 Million |
| Market Capitalization | $18.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Resverlogix Corp.'s assets at a significant premium (2.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Resverlogix Corp.'s assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Resverlogix Corp. (2001–2025)
The table below shows the annual total assets of Resverlogix Corp. from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$7.93 Million ≈ $5.74 Million |
+8.03% |
| 2024-12-31 | CA$7.34 Million ≈ $5.31 Million |
+11.87% |
| 2023-12-31 | CA$6.57 Million ≈ $4.75 Million |
-19.10% |
| 2022-12-31 | CA$8.12 Million ≈ $5.87 Million |
-18.70% |
| 2021-12-31 | CA$9.98 Million ≈ $7.22 Million |
-6.76% |
| 2020-12-31 | CA$10.71 Million ≈ $7.74 Million |
-5.91% |
| 2019-12-31 | CA$11.38 Million ≈ $8.23 Million |
-30.14% |
| 2018-12-31 | CA$16.29 Million ≈ $11.78 Million |
+96.75% |
| 2017-12-31 | CA$8.28 Million ≈ $5.99 Million |
-23.82% |
| 2016-12-31 | CA$10.87 Million ≈ $7.86 Million |
-72.90% |
| 2015-12-31 | CA$40.10 Million ≈ $29.01 Million |
+89.53% |
| 2014-12-31 | CA$21.16 Million ≈ $15.30 Million |
+599.14% |
| 2013-12-31 | CA$3.03 Million ≈ $2.19 Million |
-85.24% |
| 2012-12-31 | CA$20.50 Million ≈ $14.83 Million |
+65.68% |
| 2011-12-31 | CA$12.37 Million ≈ $8.95 Million |
+46.81% |
| 2010-12-31 | CA$8.43 Million ≈ $6.10 Million |
-0.08% |
| 2009-12-31 | CA$8.43 Million ≈ $6.10 Million |
-55.39% |
| 2008-12-31 | CA$18.91 Million ≈ $13.68 Million |
-8.71% |
| 2007-12-31 | CA$20.71 Million ≈ $14.98 Million |
+38.09% |
| 2006-12-31 | CA$15.00 Million ≈ $10.85 Million |
+86.05% |
| 2005-12-31 | CA$8.06 Million ≈ $5.83 Million |
-20.96% |
| 2004-12-31 | CA$10.20 Million ≈ $7.38 Million |
+278.45% |
| 2003-12-31 | CA$2.69 Million ≈ $1.95 Million |
+149.02% |
| 2002-12-31 | CA$1.08 Million ≈ $782.74K |
+266.44% |
| 2001-12-31 | CA$295.29K ≈ $213.61K |
-- |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more